Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Yulie Schirer"'
Autor:
Anat Idan-Feldman, Yulie Schirer, Eleni Polyzoidou, Olga Touloumi, Roza Lagoudaki, Nikolaos C. Grigoriadis, Illana Gozes
Publikováno v:
Neurobiology of Disease, Vol 44, Iss 3, Pp 327-339 (2011)
Aims: Central nervous system complications including cognitive impairment are an early manifestation of diabetes mellitus, also evident in animal models. NAP (generic name, davunetide), a neuroprotective peptide was tested here for its ability to pre
Externí odkaz:
https://doaj.org/article/2708ce2522ae41d5b1c9ce5497b7b336
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e87383 (2014)
Tauopathy, a major pathology in Alzheimer's disease, is also found in ~50% of frontotemporal dementias (FTDs). Tau transcript, a product of a single gene, undergoes alternative splicing to yield 6 protein species, each with either 3 or 4 microtubule
Externí odkaz:
https://doaj.org/article/d5ee9b1e67a84b3bb22767bf999159c3
Publikováno v:
Journal of molecular neuroscience : MN. 59(2)
NAPVSIPQ (NAP) and all D-amino acid SALLRSIPA (D-SAL) are neuroprotective peptides derived from activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF), respectively. Both proteins were shown to protect aga
Autor:
Eleni Polyzoidou, Olga Touloumi, Illana Gozes, Roza Lagoudaki, Nikolaos Grigoriadis, Anat Idan-Feldman, Yulie Schirer
Publikováno v:
Neurobiology of Disease, Vol 44, Iss 3, Pp 327-339 (2011)
Aims Central nervous system complications including cognitive impairment are an early manifestation of diabetes mellitus, also evident in animal models. NAP (generic name, davunetide), a neuroprotective peptide was tested here for its ability to prev
Autor:
Yulie Schirer, Tal Iram, Eliezer Giladi, Carmit Arviv, Sharon Furman-Assaf, Illana Gozes, Liora Rozenberg, Evgenia Maryanovsky
Publikováno v:
Journal of Alzheimer's disease : JAD. 40
NAP (NAPVSIPQ, davunetide) is a microtubule stabilizing peptide drug candidate. Here, we set out to identify NAP-like peptides that provide neuroprotection and reduce tau pathology. NAP-like peptides were derived using publically available search eng
Publikováno v:
Journal of molecular neuroscience : MN. 52(1)
We set out to identify NAP (davunetide) analogs, providing neuroprotection and reducing tau pathology, specifically addressing protection against protein misfolding. NAP (NAPVSIPQ, intranasal formulation AL-108) is a drug candidate that (1) had a sta
Publikováno v:
Alzheimer's & Dementia. 6
Publikováno v:
PLoS ONE
PLoS ONE, Vol 9, Iss 1, p e87383 (2014)
PLoS ONE, Vol 9, Iss 1, p e87383 (2014)
Tauopathy, a major pathology in Alzheimer's disease, is also found in ~50% of frontotemporal dementias (FTDs). Tau transcript, a product of a single gene, undergoes alternative splicing to yield 6 protein species, each with either 3 or 4 microtubule